Loading...
OTCMAQSZF
Market cap461kUSD
Dec 23, Last price  
0.00USD
1D
0.00%
1Q
-53.57%
Jan 2017
-97.78%
IPO
-99.05%
Name

Aequus Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:AQSZF chart
P/E
—
P/S
2.91
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.89%
Rev. gr., 5y
-28.97%
Revenues
255k
-81.53%
000701,6331,139,4241,410,2401,632,5242,592,6132,714,6981,379,772254,896
Net income
-3m
L-7.64%
-1,629,276-2,411,199-5,011,405-4,812,055-3,882,427-2,803,740-3,106,104-1,045,360-1,809,592-3,210,044-2,964,722
CFO
-2m
L+17.48%
-876,058-1,364,877-3,838,757-4,465,418-3,811,936-2,573,710-1,629,192-804,908-1,172,209-1,952,579-2,293,985
Earnings
May 07, 2025

Profile

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
URL
https://www.aequuspharma.ca/
IPO date
Mar 17, 2015
Employees
12
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
255
-81.53%
1,380
-49.17%
2,715
4.71%
Cost of revenue
3,075
3,878
3,954
Unusual Expense (Income)
NOPBT
(2,820)
(2,498)
(1,239)
NOPBT Margin
Operating Taxes
(1)
455
Tax Rate
NOPAT
(2,820)
(2,498)
(1,694)
Net income
(2,965)
-7.64%
(3,210)
77.39%
(1,810)
73.11%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,545
BB yield
-17.18%
Debt
Debt current
4,480
89
2,078
Long-term debt
1,277
1,388
329
Deferred revenue
Other long-term liabilities
Net debt
5,587
1,182
15
Cash flow
Cash from operating activities
(2,294)
(1,953)
(1,172)
CAPEX
(5)
(4)
Cash from investing activities
(508)
Cash from financing activities
2,214
(189)
2,398
FCF
(4,068)
(836)
(1,580)
Balance
Cash
170
295
2,392
Long term investments
Excess cash
157
226
2,256
Stockholders' equity
(4,294)
(1,380)
1,789
Invested Capital
5,064
783
2,180
ROIC
ROCE
418.35%
EV
Common stock shares outstanding
132,634
132,634
128,850
Price
0.04
-69.57%
0.12
-4.17%
Market cap
4,642
-68.67%
14,818
32.52%
EV
5,824
14,833
EBITDA
(2,682)
(2,368)
(1,111)
EV/EBITDA
Interest
145
214
455
Interest/NOPBT